Kornimate/medical-research-clean huggingface dataset:
circulating exosomes as potential prognostic and predictive biomarkers in advanced gastric cancer patients ("exo-ppp study")

Conditions: Gastric Cancer

Summary: exosomes are formed by inward budding of late endosomes, producing multivesicular bodies (mvbs), and are released into the environment by fusion of the mvbs with the plasma membrane. it has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced. tumor exosome production, transfer and education of bone marrow cells supports tumor growth and metastasis. in this prospective translational study, preclinical and clinical phases have been designed. on the first step, the main goal is to characterize the molecular profile of gastric cancer derived exosomes. this exosome biosignature may provide a useful diagnostic tool. as a second step, the study will evaluate the prognostic and predictive value of gastric cancer exosomes levels in plasma and kinetics in a prospectively recruited cohort of advanced gastric cancer patients during first-line chemotherapy.


Eligibility criteria:
inclusion criteria: subjects eligible for enrollment must meet all of the following criteria: 1. provide signed informed consent. the subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign informed consent, approved by the independent ethic committee (iec)/institutional review board (irb) prior to the initiation of any study-specific procedures 2. men or women aged \>= 18 years. 3. eastern cooperative oncology group performance status (ecog) \<= 2. 4. histologically confirmed adenocarcinoma of the stomach, gastroesophageal junction or esophagus. 5. metastatic disease or locally advanced disease not amenable to curative surgery. 6. radiographically assessable, non-measurable disease or measurable disease as per recist criteria. 7. life expectancy of at least 12 weeks from the time of enrollment. 8. no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. 9. no prior chemotherapy for advanced disease. exclusion criteria: subjects meeting any of the following criteria must not be enrolled in the study: 1. gastric carcinoid, sarcomas, or squamous cell cancer. 2. pregnant or lactating females. 3. significant neurological or psychiatric disorders (psychotic disorders, dementia or seizures) that would prohibit the understanding and giving of informed consent. 4. active hepatitis b or c or history of an hiv infection. 5. active uncontrolled infection.

Keywords: advanced gastric cancer
dry needling vs injection in patients with temporomandibular disorders

Conditions: Temporomandibular Disorders

Summary: the main objective is to compare the effectiveness of dry needling in improving pain and disability versus placebo, and versus infiltration, in patients with myofascial temporomandibular dysfunction in the short, medium and long term.


Eligibility criteria:
inclusion criteria: 1. subjects aged between 18 and 60 years. 2. pain of more than 6 weeks of evolution in the craniofacial region. 3. tmd with origin in the masticatory musculature according to the "dc-tmd" criteria. exclusion criteria: 1. previous injection or dry needling intervention (3 months) on the masseter muscle. 2. arthrogenous tmd. 3. history of trauma, infection in the temporomandibular joint in the last 6 months. 4. coagulation disorders. 5. pregnancy.

Keywords: dry needling temporomandibular disorders
to demonstrate the relative bioavailability of geneva and basel (anafranil) 25 mg clomipramine hydrochloride capsules under fasted conditions

Conditions: Depression

Summary: to demonstrate the relative bioavailability of geneva and basel (anafranil) 25 mg clomipramine hydrochloride capsules under fasted conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: antidepressant
mayo clinic upper digestive disease survey

Conditions: Esophageal Neoplasms; Cancer of Esophagus; Cancer of the Esophagus; Esophageal Cancer; Esophagus Cancer; Neoplasm, Esophageal; Esophagectomy; Abnormalities, Digestive System; Digestive System Abnormalities

Summary: the mayo clinic conduit report card questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. data will be used to establish the validation of the questionnaires/survey. data will also lead to the establishment of "normal" or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.

the mayo clinic conduit report card questionnaires are a compilation of standard questionnaires and questions that have been created specifically for this study some of which are patient report and others that are administered by the provider or study staff. it includes the promis global health score, modified mayo ger score questions, modified dysphagia questionnaire-30 day questions, and zubrod score. it also includes a 10-point scale to grade postoperative pain, milk assessment, modified mayo reflux score adapted from the mayo clinic reflux score, dumping score adapted from sigstad's scoring system, simple dysphagia score adapted from mellows and pinkas, stricture score adapted from blackmon, et al., pyloric spasm score, and conduit emptying score abstracted from vaezi, baker, achkar, and richter. we will also be collecting information on their demographics, operation, nutritional status, laboratory values, testing results and clinical outcomes. patients will be asked to complete the mayo clinic upper digestive disease survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime for patients who undergo surgery and at one month following diagnosis and then every three months for 1 year after diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime for patients that do not undergo surgery. the questionnaire can be completed at their clinic visit, over the telephone, or by mail using the paper form or may be completed using an electronic application. the electronic version is available for mayo clinic and non mayo clinic patients through the app store in conjunction mayo it.

Eligibility criteria:
inclusion criteria: * patients undergoing or having already undergone an esophagectomy or esophageal reconstruction.
enhancing connections program in improving communication between patients with incurable cancer and their children

Conditions: Advanced Malignant Neoplasm

Summary: this pilot clinical trial studies the use of the enhancing connections program in improving communication between patients with incurable cancer and their children. the enhancing connections program is an educational program that may provide patients with new competencies to improve communication with their children and help them to cope with their parent's incurable cancer.

primary objectives: i. to test the feasibility of the study protocol in advanced cancer patients (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics). ii. to evaluate the short-term impact of the program on the diagnosed parents' and children's adjustment using a within group design (pre- and post-test design). iii. to compare outcomes from the enhancing connections program with outcomes obtained from the completed phase iii trial (between group design). outline: patients participate in enhancing connections program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.

Eligibility criteria:
inclusion criteria: * parents will be eligible if they have a diagnosis of incurable cancer of any type * read and write english among their languages of choice * have a child 5-17 years old living at home who has been told their parent's cancer diagnosis * the child does not have learning challenges exclusion criteria: * parents will be excluded if they are enrolled in hospice at time of enrollment; (however, they will be allowed to continue in the study if they enroll in hospice after beginning the study) * parents will be ineligible if their child lives in the home less than 50% of the time
association between hepatitis c infection and renal cell carcinoma

Conditions: Hepatitis C; Renal Cell Carcinoma; Colorectal Cancer

Summary: the purpose of this study is to determine if there is an association between hepatitis c infection and kidney cancer. all patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered to be tested for hepatitis c. the control group will be colon cancer patients. both groups would be of recent diagnosis (6 months).


Eligibility criteria:
inclusion criteria: * male and female patients 18 years or older in whom renal cell carcinoma is suspected and are scheduled for either biopsy or partial or total nephrectomy. diagnosis within 6 months. * male and female patients 18 years or older in whom colorectal cancer has been diagnosed within the last 6 months exclusion criteria: * patients who are unwilling to provide consent * patients who decline to complete a questionnaire * patient in who blood sample cannot be obtained * diagnosis of renal cell carcinoma or colon cancer greater than 6 months

Keywords: hepatitis c renal cell carcinoma colorectal cancer
risk stratification using midregional proadrenomedullin in the ed

Conditions: Patients Presenting With Suspicion of Infection to the ED

Summary: emergency departments (ed) are becoming increasingly over-crowded, with patients facing prolonged waiting times. therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ed. the rationale of this ideal+ study is to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker mr-proadm. this will has already been tested in the ideal - pilot study and results should be confirmed with this ideal+ study.


Eligibility criteria:
inclusion criteria: 1. consecutive patients presenting to the ed with suspicion of infection 2. age ≥18 years 3. written informed consent obtained exclusion criteria: 1. patients with sars-cov-2 infection 2. recent major trauma or surgery 3. end stage renal failure requiring dialysis 4. terminal disease and/or very severe medical co-morbidity where death has to be expected in the next 6 months, e.g. due to malignancy, cardiac, renal or hepatic failure 5. patients whose source of infection always requires hospital admission or never requires hospital admission. 6. patients who cannot be discharged for other than medical reasons 7. patient participates in any other interventional clinical trial 8. patients with active abusive drug use 9. pregnant or lactating women 10. patients who are institutionalized by official or judicial order 11. dependents of the sponsor, the cro, the study site or the investigator
comparison of emergence and oxygenation during one-lung ventilation with desflurane and propofol anesthesia

Conditions: Lung Cancer

Summary: which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?

the investigators plan to investigate the effects of desflurane on oxygenation (prevention of hpv) of olv compare with propofol which is used in general anesthesia for lung resection. transesophageal echocardiography (tee) wiill be used to measure pulmonary blood flow during surgery visible and successively. to confirm the effect of hpv by measuring the change in pulmonary blood flow. the correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.

Eligibility criteria:
inclusion criteria: * patients agree to participate in the study * patients undergoing lung cancer surgery requiring one-lung ventilation. * american society of anesthesiologists physical status class 1 or 2 exclusion criteria: * patients with any of the following will be excluded from lung cancer patients. * new york heart association classification more than 2 * respiratory dysfunction vital capacity or percent predicted forced expiratory volume in one second is less than 50 % * pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmhg * coagulation dysfunction * the administration of steroids and immunosuppressive agents within 3 months prior to surgery * infection with active inflammation * pneumonectomy patients * cases of epidural anesthesia is contraindicated

Keywords: one-lung ventilation, oxygenation
intracutaneous sterile water injections for acute low back pain in the emergency department

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy of intracutaneous sterile water injections (iswi) for treatment of acute low back pain in patients presenting to the emergency department. the primary aim is to determine if iswi provides pain relief for acute low back pain in the ed. the secondary aim is to evaluate whether iswi provides improved patient satisfaction in the ed setting. the hypothesis is that iswi will improve pain amongst patients presenting with acute low back pain to the ed.

the purpose of this study is to evaluate the efficacy of intracutaneous sterile water injections (iswi) for treatment of acute low back pain in patients presenting to the emergency department. the primary aim is to determine if iswi provides pain relief for acute low back pain in the ed. the secondary aim is to evaluate whether iswi provides improved patient satisfaction in the ed setting. the hypothesis is that iswi will improve pain amongst patients presenting with acute low back pain to the ed. this pilot study will use a randomized controlled trial design to compare the effects of iswi to intracutaneous dry injections in patients presenting to the ed with acute low back pain.

Eligibility criteria:
\*\*patients must be able to get care at nellis air force base (a military installation) in order to participate in this study\*\* inclusion criteria: * active duty and dod beneficiaries aged 18 to 64 years. * presenting to the ed with a chief complaint of acute low back pain of less than 2 weeks in duration. * pain severity on presentation of greater than or equal to 5/10 on visual analogue scale. exclusion criteria: * traumatic low back pain * new weakness or neurologic deficit * new loss bowel/bladder control * back pain above t12 * active cancer * currently taking anticoagulant medications * signs of infection or trauma over the injection site * non-english speaking * pregnancy

Keywords: low back pain sterile water injection emergency department sterile water acute low back pain
omacor in prevention of cardiovascular events in patients undergoing chronic hemodialysis

Conditions: Kidney Failure, Chronic

Summary: the aim of this investigator initated study is to examine the effect of omacor (omega-3-acid ethyl ester 90) on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis, who has previously experienced a cardiovascular event.

patients with renal failure have a high incidence of cardiovascular disease and increased premature mortality. omega-3 polyunsaturated fatty acids from fish are known to have cardioprotective effects in subects with normal renal function. the aim of present study is to examine the effect of omacor (omega-3-acid ethyl ester 90) on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis, who has previously experienced a cardiovascular event. design: a prospective, randomised, placebo controlled study. 2 year treatment period.

Eligibility criteria:
inclusion criteria: * males and females above 18 years of age * patients having been treated with chronic hemodialysis for at least 6 months * patients with documented cardiovascular disease, at least one of the following 1. angina pectoris 2. previous acute myocardial infarction 3. previous ptca/cabg or demonstated atheroclerosis after coronary angio 4. previous transitory cerebral ischemia 5. previous apoplexia cerebri 6. symptoms of peripheral vascular disease * written informed consent exclusion criteria: * active malignant disease, except basal cell carcinoma or spinocellular carcinoma * patients undergoing peritoneal dialysis * any condition associated with a risk of poor compliance, as judged by investigator * pregnant or breastfeeding * participation in other clinical studies involving treatment with drugs.

Keywords: chronic renal failure hemodialysis omacor (omega-3-acid ethyl ester 90) intervention study cardiovascular events mortality
molecular analysis of retinoblastoma

Conditions: Retinoblastoma

Summary: retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000 children. retinoblastoma is more prevalent in central america, where most patients present with advanced intraocular and extraocular disease. therefore, we have formed collaboration with central american investigators to provide us with frozen retinoblastoma tumors from patients undergoing routine enucleation. the objective of this protocol is to begin to identify the mutations and gene expression changes that occur in retinoblastoma cells following rb1 gene inactivation in order to more effectively target chemotherapy for treating bilateral retinoblastoma.

this is a biology protocol with no treatment regimen associated. following routine enucleation of the retinoblastoma affected eye, a portion of the tumor will be removed and flash frozen and sent to st. jude for rna and dna analysis. some tissue will undergo histopathological analysis and tissue microarrays will be isolated.

Eligibility criteria:
inclusion criteria: * must have clinical diagnosis of retinoblastoma (to be confirmed histologically after enucleation) * legal guardians must willing to sign an informed consent indicating that they are aware of this study and its possible benefits. legal guardians will be given a copy of the consent form. * patient is being seen at this ahopca institution: exclusion criteria: * ophthalmologist or oncologist is concerned that sampling will interfere with staging. * diagnosis other than retinoblastoma. * affiliated hospital is unable to provide pathologic evidence of retinoblastoma.
treatment of patients with major depressive disorder with mk0869 (0869-066)(completed)

Conditions: Major Depressive Disorder

Summary: a clinical study to determine the efficacy and safety of an investigational medication (mk0869) in the treatment of depression

the duration of treatment is 1 year.

Eligibility criteria:
major depressive disorder
primary obstructive megaureter management in eastern interregional area

Conditions: Congenital Obstructive Megaureter

Summary: congenital obstructive megaureter is a urinary malformation affecting the ureterovesical junction and causing obstruction to the flow of urine. it is the second most common cause of hydronephrosis. this malformation affects four times more boys than girls and is bilateral in 25% of cases. it is also associated with contralateral renal dysplasia in 15% of cases. the obstruction is linked to aperistalsis and hypertrophy of the circular muscle bundles and increased collagen 1 level. this malformation is accessible to antenatal screening from the second trimester. it falls within the scope of cakut and requires regular monitoring. indeed, this uropathy can cause repeated pyelonephritis, kidney scarring and affected kidney function.


Eligibility criteria:
inclusion criteria: * minor patient (from 1 to 17 years old) * patient treated between january 2010 and december 2017 in one of the participating centers for an obstructive congenital mega-ureter * subject (and/or his parental authority) not having expressed, after information, his opposition to the reuse of his data for the purposes of this research exclusion criteria: * subject (and/or his parental authority) having expressed, after information, his opposition to the reuse of his data for the purposes of this research

Keywords: congenital obstructive megaureter urinary malformation ureterovesical junction hydronephrosis renal dysplasia
il-6 as a biomarker for personalized treatment of pr

Conditions: Rheumatoid Arthritis

Summary: several studies have shown the relevance of the il6 level before treatment or after 6 months, as a predictive biomarker for the persistence of remission. the il6 assay is now routinely available using the instruments available at the montpellier university hospital and with reagents provided by the roche laboratory. moreover medical practices should incorporate this parameter. however, relevant threshold shlould be defined before being able to integrate biomarkers such as il6 for monitoring bdmards in an algorithm. the medical staff of clinical immunology unit has decided to include the dosage of il-6 during a routine biological assessment during patient visit to follow the new eular recommendations . this measument will be perfom in addition to the crp and biochemical parameters on subjects with active ra or in remission upon the introduction of biological treatments or jaki or during remission after at least 6 months of treatment. from march to july 2021, 200 patients will beenrolled and will benefit of this assessement. the investigators will retrospectively define clinical correlations with serum il6 levels in order to define a threshold. in the second stage, a decisional algorithm based on the results of this project will be create. this will allow an improvement of the medical practices thanks to the integrationof of serum il6 dosage as a standard during patients visits. the il-6 assay will be performed on the e801 module of the cobas lines (roche diagnostics) currently in place in the biochemistry and hormonology laboratory. the elecsys® il-6 - roche diagnostics test, high sensitivity, is an electrochemiluminescence immunoassay.


Eligibility criteria:
inclusion criteria: * 18 to 65 years old * patients with rheumatoid arthritis according to 2010 acr/eular criteria who have one of the following conditions: * subjects with active ra (das28\> 3.6) who have failed methotrexate treatement and with a standard medical care for which an indication for biotherapy is retained or * subjects with remission of ra (das28\<2.6) for which a biotherapy delay (anti-tnf or anti-il6r or jaki) is proposed. exclusion criteria: - age under 18 years old

Keywords: il-6 biomarker